Shots:
- The US FDA has granted ODD to CAL101 for the treatment of idiopathic pulmonary fibrosis (IPF)
- CAL101 (IV, QM for 7mos.) is being investigated in a P-II (AURORA) trial against PBO in 150 IPF pts, with enrolment open in the sites across US, UK, EU, Turkey, & South Korea, evaluating lung function per forced vital capacity as 1EP
- CAL101, a monoclonal antibody targeting the DAMP protein S100A4, aims to restore tissue homeostasis by inhibiting downstream pathways driving persistent & maladaptive scar formation in IPF
Ref: Calluna Pharma| Image: Calluna Pharma| Press Release
Related News:- Sanofi’s Rilzabrutinib Secures the EMA’s Orphan Drug Designation to Treat IgG4-Related Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
